Results

Total Results: 1,546 records

Showing results for "drug".

421. PREGNANCY, INCLUDING PRETERM BIRTH #12 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pregnancy-horizon-scan-high-impact-1312.pdf
     December 01, 2013 - similar drugs in the same class are read separately), and then topics in the same class of a device, drug … Food and Drug Administration (FDA) ruled recently that this intervention is not subject to FDA approval … acquired from a pharmacy; the university does not cover or subsidize cost of the drug.6 Teva Pharmaceutical … Food and Drug Administration stated it would not intervene to require regulation of the machine.7 On … Obama administration drops its appeal of Plan B ruling, will widen access to drug. [internet].

422. Comparative Effectiveness Review (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/osteoarthritis-pain-2006_appendixes.pdf
     January 01, 2006 - Pharmacokinetics, Indications and Dosing of Included Drugs Drug and Trade Name (Trade names … mg/day in 3- 4 Renal impairment: initiate with lowest recommended dosage, monitor closely Drug … or within 7 days of stopping drug during 9 months since start of treatment; when not known if … patient was taking drug at the time of the event, only those events that had occurred within … Both trials favored etodolac over the comparator drug.

423. Evidence-based Practice Center Systematic Review Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/diabetes-update-2015_disposition-comments.pdf
     January 01, 2015 - the Methods section of the Executive Summary that we searched ClinicalTrials.gov and the Food and Drug … drug 1". … We have changed the legend for the hypoglycemia figure to say, "Fewer events with drug 2/drug 1." … What are the specific pros and cons of the choice of a second drug to add to metformin when greater … Note glibenclamide and glyburide are the same drug, right? Needs a table footnote.

424. Despite steadily increasing health care expenditures in the United States, improved health outcomes and quality remain elusive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/medical-interventions-comparing_methods.pdf
     November 01, 2008 - led to a series of Medicare reforms passed by Congress in 2003. 3 These reforms included a new drug … Accessed November 2007. 3 Medicare Prescription Drug, Improvement, and Modernization Act of 2008

425. Despite steadily increasing health care expenditures in the United States, improved health outcomes and quality remain elusive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/methodsguide_slutsky_comparing_medical_interventions.pdf
     November 01, 2008 - led to a series of Medicare reforms passed by Congress in 2003. 3 These reforms included a new drug … Accessed November 2007. 3 Medicare Prescription Drug, Improvement, and Modernization Act of 2008

426. Layout 1 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/type-2-diabetes-medications-update_executive.pdf
     March 01, 2011 - Food and Drug Administration (FDA). … Two-drug combination therapies with metformin (such as metformin plus thiazolidinediones, metformin plus … Few studies included insulin added to oral medications or compared other two-drug combination therapies … We were unable to draw any useful conclusions about CHF risk from other drug comparisons of interest, … their results by the combination therapy, which includes the background medication(s) plus the study drug

427. Crosscutting-Horizon-Scan-High-Impact-1312 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/crosscutting-horizon-scan-high-impact-1312.pdf
     December 01, 2013 - Digital Medicines (Proteus Digital Health Feedback System) for Chronic Conditions Requiring Long-term Drug … Food and Drug Administration for the monitoring device in March 2010 and marketing clearance for the … Once activated, the sensor transmits digital information regarding the drug taken, its dose, and time … Food and Drug Administration (FDA). 510(k) summary for Raisin personal monitor [K093976]. … Food and Drug Administration (FDA); 2010 Mar 25 [accessed 2010 Dec 27]. [10 p].

428. #06 Developmental Delays ADHD, and Autism (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/developmental-delays-horizon-scan-high-impact-1306.pdf
     June 01, 2013 - similar drugs in the same class are read separately), and then topics in the same class of a device, drug … Food and Drug Administration (FDA) has approved intranasal oxytocin for inducing uterine contractions

429. Topic 0494 Tacrolimus Monitoring and Treatment Renal Transplantation NSD FINAL (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/TND_0583-131115.pdf
     March 13, 2013 - Cyclosporine, has a narrow therapeutic window between efficacy and toxicity, thereby requiring monitoring of drug … mainly as CNI-minimization, CNI-avoidance, or CNI-withdrawal protocols, seek to reduce the amount of drug

430. Arthritis and Nontraumatic Joint Disease (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/01_-arthritis_potential_high_impact_june_2012.pdf
     January 01, 2012 - similar drugs in the same class are read separately), and then topics in the same class of a device, drug … lists the seven topics for which (1) preliminary phase III or later phase data were available for drug …  Key Expert Comments: Overall, experts thought that the drug might address the unmet need for a … Food and Drug Administration (FDA)-compliant manner will be needed in many locations where there may … tyrosine kinase inhibitor that is being investigated as a targeted disease-modifying antirheumatic drug

431. Evidence-based Practice Center Systematic Review Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/stroke-atrial-fibrillation_research-protocol.pdf
     January 30, 2012 - Food and Drug Administration (FDA)-approved low-molecular-weight heparins (e.g., bemiparin, certoparin … Food and Drug Administration; HAS-BLED = hypertension, abnormal renal/liver function, stroke, bleeding … We will use several approaches to identify relevant gray literature, including requests to drug and … Food and Drug Administration (FDA) device registration studies and new drug applications. … Food and Drug Administration GWTG Get With The Guidelines HAS-BLED hypertension, abnormal renal/liver

432. Microsoft Word - 3-DKE274__ACEI-ARB-DRI__Comments_Disposition_Table-21_Jan_2011 cyk _2_.docx (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/ace-inhibitor-arb-update_disposition-comments.pdf
     October 07, 2011 - recommendation for the use of these products in any manner other than as approved by the Food and Drug … ONTARGET is that combination therapy had higher adverse event rates but no more benefit than a single drug … The key questions 1 and 2 specifically examine cardiovascular events and adverse events between drug … Consideration of drug specific characteristics such as variations in tissue specificity, side effect … Furthermore, we note that the report introduces some of the pharmacological differences between drug

433. Systematic Review of Intermittent Inhaled Corticosteroids and of Long-acting Muscarinic Antagonists for Asthma (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/asthma-pharmacologic-treatment_research-protocol.pdf
     December 27, 2016 - of the pharmacologic interventions include more than one class of medications, in which case one drug … some of the pharmacologic comparators include more than one class of medications, in which case one drug … the abstract stage consistent with the process described by the Methods Guide.10 FDA=Food and Drug … Published online September 14, 2016; republished December 27, 2016 10 not on the individual drug … Drug therapies either as individual or combination products of inhaled corticosteroids, long-acting

434. Kidney-Disease-Medicine Surveillance (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/kidney-disease-medicine_surveillance.pdf
     October 01, 2012 - would produce prima facie evidence that a conclusion was out of date, such as the withdrawal of a drug … Is the portion of the CER that is probably or certainly out of date an issue of safety (a drug withdrawn … from the market, a black box warning) or the availability of a new drug within class (the latter being … original key questions, the conclusions of the original report, the results of the literature and drug … screening.tw. or exp drug evaluation,preclinical/ 3. 1 not 2 4.

435. - (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/crohns-disease-future_research.pdf
     July 01, 2016 - first biologic tumor necrosis factor (TNF)-alpha inhibitor, infliximab, was approved by the Food and Drug … New Drug Application & Biologic License Application Efficacy Supplements (Approved CY 2008) [Internet … New Drug Application & Biologic License Application Efficacy Supplements (Approved CY 2008) [Internet … : Cimzia Drug: Mesalamine Estimated enrollment: 24 Sponsor OR PI and Collaborator(s): Milton S. … : Adalimumab Drug: 6 Mercaptopurine Estimated enrollment: Sponsor OR PI and Collaborator(s):

436. Restless-Legs Executive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/restless-legs_executive.pdf
     November 01, 2012 - Dopamine agonists can result in a treatment complication called augmentation, which is a drug-induced … Central, the International Controlled Trials Registry Platform (ICTRP), Clinicaltrials.gov, Food and Drug … Results We organized results by Key Question and by class of drug/therapy. … Four studies investigated multiple fixed doses of the drug in separate study arms.25,34,37,39 IRLS … Augmentation, a drug-induced exacerbation of the disease, can occur with dopaminergic drugs.

437. Disposition of Comments Report for The Effectiveness and Risks of Long-Term Opioid Treatment of Chronic Pain (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/chronic-pain-opioid-treatment_disposition-comments.pdf
     September 29, 2014 - We have previously submitted comments to FDA regarding “Impact of Approved Drug Labeling on Chronic … Our prescription drug abuse project works to develop and support policies that will help reduce the … The Pew Charitable Trusts recognizes prescription drug abuse as a public health crisis in the United … iii Food and Drug Administration (FDA), “Public Health Advisory: Methadone Use for Pain Control May … A history of being prescribed controlled substances and risk of drug overdose death.

438. Maternal, Fetal, and Child Outcomes of Mental Health Treatments in Women: A Systematic Review of Perinatal Pharmacological Interventions (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/cer-236-maternal-fetal-child-outcomes-disposition-comments.pdf
     April 15, 2021 - • The draft report included references to Food and Drug Administration letter categories for fetal … lot of studies did not specify the disorder (they were based on current vs. past exposure to the drug … treatment comparison data and the other comparator data in one table so that readers can sort by drug … The title of this table should be changed to “Drug labeling related to pregnancy and nursing”. … Calibration curves were constructed for each antipsychotic drug assay with free human plasma by the

439. PHS 398 (Rev. 9/04), Continuation Page (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/upenn-final-report-2005-certs-ce-supplement.pdf
     January 01, 2005 - A study funded by the US Food and Drug Administration and performed by the Research Triangle Institute … physician offices, pharmacies, etc.1 The results of this study suggested that the demographic and drug … As this study was conducted supplementary to an ongoing R01 investigating drug-induced SCD/VA, this … Incidence and antecedent drug exposures. Arch. Dermatol. 127, 831-838 (1991). 4.

440. PHS 398 (Rev. 9/04), Continuation Page (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/administrative-data-validity_research.pdf
     January 01, 2007 - A study funded by the US Food and Drug Administration and performed by the Research Triangle Institute … physician offices, pharmacies, etc.1 The results of this study suggested that the demographic and drug … As this study was conducted supplementary to an ongoing R01 investigating drug-induced SCD/VA, this … Incidence and antecedent drug exposures. Arch. Dermatol. 127, 831-838 (1991). 4.